Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chimeric dengue serotype · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Received monovalent Vero dengue vaccine in Study DIV12 |
| 2 | EXPERIMENTAL | Received Yellow fever vaccine in Study DIV12 |
| 3 | EXPERIMENTAL | Flavivirus-naive subjects |
| Name | Type | Description |
|---|---|---|
| Chimeric dengue serotype (1, 2, 3, 4) | BIOLOGICAL | 0.5 mL, Subcutaneous, 1 dose |
Inclusion Criteria : * Aged 18 to 40 years on the day of inclusion. * Informed consent form signed. * For a woman, inability to bear a child or negative serum pregnancy test. * Completed the one-year follow-up of Study DIV12. * Able to attend all scheduled visits and to comply with all trial proced...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 1 | - | Undisclosed |
Chimeric dengue serotype is an investigational monoclonal antibody being developed for dengue, including dengue fever, dengue hemorrhagic fever, and dengue virus infection. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Chimeric dengue serotype is being developed by Sanofi, a biopharmaceutical company traded on the stock exchange under the ticker SNY. The drug is in Phase 2 clinical development for dengue and related conditions.
Chimeric dengue serotype is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. A Phase 2 clinical trial has been completed to evaluate its safety and immunogenicity in adult subjects.
Chimeric dengue serotype has one completed Phase 2 clinical trial, identified as NCT00730288, titled 'Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects.' This trial enrolled 35 participants in Australia and included healthy volunteers aged 18 years and older.
Yes, Chimeric dengue serotype is the same as ChimeriVax™ Dengue Tetravalent Vaccine. The Phase 2 clinical trial NCT00730288, which evaluated the drug, used this alternative name in its title. Both names refer to the same investigational dengue vaccine candidate.